• Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel

    Learn more

Immunicum is listed on NASDAQ Stockholm under the ticker IMMU

About us

Developing innovative cancer immunotherapies

Immunicum is advancing a novel cell-based approach to target solid tumors.

Learn more
About